Biib stock price target

Biogen (BIIB) Gets a Buy Rating from Oppenheimer - Markets

7 Feb 2020 Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB ) to $390.00 (from $338.00) while maintaining a Outperform  5 Feb 2020 Baird's Brian Skorney believes today's monster move in Biogen (BIIB +16.7%), boosting his fair value target to $290 (12% downside risk) from $250. Most Heavily Shorted Stocks - February 2020 My price target is 617. 5 Apr 2018 Analysts have long been a fan of biotech stock Biogen Inc (NASDAQ:BIIB). Of the 23 brokerage firms that have coverage on BIIB, 16 say to buy  22 Mar 2019 Biogen stock was falling again, as more analysts downgraded the shares Biogen stock (BIIB) is off 26.4% year to date, and has fallen nearly  21 Mar 2019 All in all, BIIB stock has gotten a whopping 9 downgrades, and numerous price target cuts. Out of 23 analysts polled by TipRanks in the last 3  8 Feb 2020 Baird analyst Brian Skorney raised his price target for Biogen (BIIB) to $290 from $250, after the PTAB released its decision on the Mylan (MYL) 

Biogen (NASDAQ:BIIB) had its target price upped by Nomura from $320.00 to $392.00 in a research note published on Friday morning, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts …

21 Mar 2019 All in all, BIIB stock has gotten a whopping 9 downgrades, and numerous price target cuts. Out of 23 analysts polled by TipRanks in the last 3  8 Feb 2020 Baird analyst Brian Skorney raised his price target for Biogen (BIIB) to $290 from $250, after the PTAB released its decision on the Mylan (MYL)  26 Jun 2019 Stocks quotes in this article: BIIB Prices are at the top end of a small accumulation pattern with an upside price target of $291 being projected. 23 Oct 2019 he said raising his 12-month price target to $365. That's about $140 above where shares were trading before Tuesday's announcement. 12 Jul 2018 BIIB Stock Forecast: Biogen Inc. Skyrockets As New Drug Brings According to the Alzheimer's Association, Alzheimer's care costs will be over  BIIB Price Target and Analyst Ratings (Biogen) | MarketBeat Nov 09, 2019 · 31 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $325.40, suggesting that the stock has a possible upside of 9.81%. The high price target for BIIB is $410.00 and the low price target for BIIB is $231.00.

Based on 25 analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $342.91 with a high forecast of $420.00 and a 

Learn about BIIB with our data and independent analysis including price, star analysts' nine 'exponential technology' themes and some undervalued stocks  In depth view into BIIB (Biogen) stock including the latest price, news, dividend history, earnings information and financials.

Biogen (NASDAQ:BIIB) Price Target Increased to $302.00 by ...

Why Investors Need To Watch Biogen Inc. (BIIB)? | News Heater Mar 04, 2020 · BIIB Stock Insider Trading. Reports are indicating that there were more than several insider trading activities at Biogen Inc. (BIIB), starting from Posner Brian S, who sold 1,055 shares at the price of $292.35 back on Dec 02. After this action, Rushing now owns 6,995 shares of Biogen Inc., valued at $308,429 with the latest closing price. Biogen Price Target | BIIB View Price Target for BIIB Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. BIIB Price Target - ETF Channel The median BIIB price target (a different metric than the average or mean) was $320.0 as of 2020-03-11, the highest BIIB price target in the range was $420.0 while the lowest BIIB price target in the range was $245.0, with a standard deviation of $45.633. Get the latest Zacks research report on BIIB — FREE Ideas and Forecasts on BIOGEN INC — NASDAQ:BIIB — TradingView

Biogen Inc. BIIB. Real-time BATS EXCHANGE - 03/09 05:03:55 pm. 326.47USD. +2.68%. Consensus 

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (79.2%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - Stock Comparison: Compare Biogen Inc. (BIIB) to Other Stocks. Mar 27, 2020 · Online Stock Comparison - Compare Biogen Inc. (BIIB) to four other stocks with NASDAQ.com's stock comparison tool. Biogen Inc. [BIIB] stock Initiated by Barclays analyst ...

5 Apr 2018 Analysts have long been a fan of biotech stock Biogen Inc (NASDAQ:BIIB). Of the 23 brokerage firms that have coverage on BIIB, 16 say to buy